Mobile

Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006682-33

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess progression free survival (PFS) of AG-013736 in combination with paclitaxel and carboplatin (Arm A) versus bevacizumab in combination with paclitaxel and carboplatin (Arm B).

Critère d'inclusion

  • First line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC)

Liens